🔗 Visit the ClinicalTrials.gov page for NCT00741260
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. | Br J Cancer | 2012 | 1.12 |
| 2 | Treatment of HER2-positive breast cancer. | Breast | 2013 | 1.09 |
| 3 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. | J Clin Oncol | 2014 | 0.92 |
| 4 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. | Am J Cancer Res | 2015 | 0.88 |
| 5 | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. | Breast Cancer (Auckl) | 2014 | 0.87 |
| 6 | Profile of neratinib and its potential in the treatment of breast cancer. | Breast Cancer (Dove Med Press) | 2015 | 0.86 |
| 7 | Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. | Curr Breast Cancer Rep | 2014 | 0.79 |